The U.S. Food & Drug Administration on Friday announced it was revoking its approval of the breast-cancer treatment Avastin (bevacizumab). The FDA said the drug has not been shown to delay tumor growth and brings potentially life-threatening risks.
“Nor is there evidence that use of Avastin will either help women with breast cancer live longer or improve their quality of life,” the FDA said in a statement.
Avastin will remain on the market as an approved treatment for other cancers, including colon, lung, kidney and brain cancer, the agency said.
RELATED LINKS
Nov. 18, 2011, FDA.gov, “FDA Commissioner Removes Breast Cancer Indication from Avastin Label” – FDA news release about the decision.
Nov. 18, 2011, Associated Press/via WashingtonPost.com, “FDA says Avastin should no longer be used for breast cancer, citing no proof it extends life”
by 
